Friso MUM, the activity of a helath supplement during pregnancy and lactation.

The effect of high DHA-fish oil and arachidonic acid (AA) suppletion during pregnancy and lactation on LCP status of mother and child and on the neurological development of the baby.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25238

Enrollment

300

Registered

2005-09-12

Start date

2004-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(Neurological development)

Interventions

Everybody recieves a multivitamin supplement (desgined for pregnant women). Next to that we compare placebo vs DHA vs DHA/AA.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Apparently healthy pregnant women; 2. Para 0 or 1; 3. Inclusion should take place prior to the 16th week of pregnancy.

Exclusion criteria

Exclusion criteria: 1. Hyperemesis Gravidarum 2. Vegetarian of Vegan; 3. Pregnant with twins; 4. Diabetes Mellitus type 1; 5. Usage of helath supplements with fatty acids, tryptophan or melatonin.

Design outcomes

Primary

Measure	Time frame
Neurological Development of the baby (Neurological Optimality Score and General Movements).	—

Secondary

Measure	Time frame
1. Mood, cognitive functioning and sleeping rhythm of the mother; 2. LCP status in red blood cells of mother (16th and 36th week) and child (12 weeks after birth), umbilical cord, breast milk (2 and 12 weeks after birth).	—

Contacts

Public ContactSaskia A. Goor, van

University Medical Center Groningen (UMCG), Department of Pathology and Laboratory Medicine, Postblok CMC-V-1 floor, P.O. box 30001

s.a.van.goor@lc.umcg.nl+31 (0)50 3610399

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)